Harpoon Therapeutics Inc. (HARP)
23.01
0.02 (0.09%)
At close: Mar 08, 2024, 9:00 PM
0.09% (1D)
| Bid | n/a |
| Market Cap | 865.08M |
| Revenue (ttm) | 37.34M |
| Net Income (ttm) | -30.86M |
| EPS (ttm) | -1.53 |
| PE Ratio (ttm) | -15.03921568627451 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 6,401,494 |
| Avg. Volume (20D) | 1,129,503 |
| Open | 23.00 |
| Previous Close | 22.99 |
| Day's Range | 22.99 - 23.02 |
| 52-Week Range | 3.11 - 23.21 |
| Beta | 1.55 |
About HARP
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung can...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 8, 2019
Employees 45
Stock Exchange NASDAQ
Ticker Symbol HARP
Website https://www.harpoontx.com